JPH06505487A - 食道癌の治療用医薬組成物 - Google Patents

食道癌の治療用医薬組成物

Info

Publication number
JPH06505487A
JPH06505487A JP4507807A JP50780792A JPH06505487A JP H06505487 A JPH06505487 A JP H06505487A JP 4507807 A JP4507807 A JP 4507807A JP 50780792 A JP50780792 A JP 50780792A JP H06505487 A JPH06505487 A JP H06505487A
Authority
JP
Japan
Prior art keywords
hydroxy
days
topotecan
day
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP4507807A
Other languages
English (en)
Japanese (ja)
Inventor
ジョンソン，ランドール・キース
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of JPH06505487A publication Critical patent/JPH06505487A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP4507807A 1991-02-21 1992-02-07 食道癌の治療用医薬組成物 Pending JPH06505487A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65893691A 1991-02-21 1991-02-21
US658,936 1991-02-21
PCT/US1992/001029 WO1992014470A1 (en) 1991-02-21 1992-02-07 Treatment of esophageal cancer

Publications (1)

Publication Number Publication Date
JPH06505487A true JPH06505487A (ja) 1994-06-23

Family

ID=24643326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4507807A Pending JPH06505487A (ja) 1991-02-21 1992-02-07 食道癌の治療用医薬組成物

Country Status (8)

Country Link
EP (1) EP0572563A4 (pt)
JP (1) JPH06505487A (pt)
KR (1) KR930702985A (pt)
AU (1) AU664172B2 (pt)
CA (1) CA2104449A1 (pt)
MX (1) MX9200725A (pt)
PT (1) PT100154A (pt)
WO (1) WO1992014470A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502116A (ja) * 2005-07-27 2009-01-29 オンコセラピー・サイエンス株式会社 食道癌を診断する方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395541B1 (en) 1996-05-23 2002-05-28 The Rockefeller University Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
WO2001066144A2 (en) * 2000-03-08 2001-09-13 Rhode Island Hospital, A Lifespan Partner Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
CA2404431C (en) 2000-03-27 2011-06-07 Thomas Jefferson University Guanylyl cyclase c in the detection of stomach and esophageal cancers
ES2371171B1 (es) * 2010-06-08 2012-11-16 Consejo Superior De Investigaciones Científicas (Csic) Derivados de camptotecina como agentes antitumorales.
CN102659800B (zh) * 2012-05-11 2014-09-03 中国药科大学 一类低氧激活抗肿瘤化合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01186893A (ja) * 1987-12-01 1989-07-26 Smithkline Beckman Corp 水溶性カンプトテシン類似体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01186893A (ja) * 1987-12-01 1989-07-26 Smithkline Beckman Corp 水溶性カンプトテシン類似体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502116A (ja) * 2005-07-27 2009-01-29 オンコセラピー・サイエンス株式会社 食道癌を診断する方法
US8771963B2 (en) 2005-07-27 2014-07-08 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer

Also Published As

Publication number Publication date
EP0572563A1 (en) 1993-12-08
PT100154A (pt) 1993-05-31
CA2104449A1 (en) 1992-08-22
WO1992014470A1 (en) 1992-09-03
AU664172B2 (en) 1995-11-09
KR930702985A (ko) 1993-11-29
AU1540692A (en) 1992-09-15
EP0572563A4 (en) 1993-12-29
MX9200725A (es) 1992-09-01

Similar Documents

Publication Publication Date Title
ES2204894T3 (es) Composicion que contiene cisplatino y topotecan como agente antitumoral.
TW202023563A (zh) 新穎喹唑啉egfr抑制劑
JPH07501818A (ja) 結腸直腸癌の治療
JPH06505487A (ja) 食道癌の治療用医薬組成物
US5674872A (en) Treatment of ovarian cancer
JP2738979B2 (ja) 非小細胞肺癌の治療
JP2778632B2 (ja) 卵巣癌の治療用医薬組成物
TWI228417B (en) A composition for inhibiting neoplastic cells
HK1095517A (en) Pharmaceutical composition for the treatment of ovarian cancer
HK1099549A (en) A pharmaceutical composition for use in the treatment of ovarian cancer in a human afflicted therewith
HK1012265B (en) Use of topotecan in the manufacture of a medicament for use in the treatment of ovarian cancer
HK1012267B (en) Use of topotecan in the treatment of non-small cell lung carcinoma
HK1062892A (en) Combination chemotherapy involving topotecan and a platinum coordination compound
HK1012268B (en) Composition containing cisplatin and topotecan as antitumor agent